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Cystic fibrosis, breath pentane, and lipid
peroxidation
SIR,-Dr Weitz and colleagues (April 20, p 933) report the value
of breath pentane analysis as an index of increased lipid peroxi-
dation in vivo. However, Weitz et al fail to indicate the potential
shortcomings of the method, as we are beginning to see in the
context of cystic fibrosis.
We have found that techniques involving hydrocarbon-
contaminated inspired air, as used by Weitz et al, produce
unreliably high results for breath pentane analysis. Increased
quantities of breath pentane do not provide a specific marker of
increased lipid peroxidation since they may accompany infection of
the small intestine by colonic bacteria. Reassessment after one week
of neomycin helps to assess the contribution of this possible artefact
in our patients.1 In addition, isolated measurement of breath
pentane does not give a global view of free-radical oxidation of lipids
in vivo because pentane is only one of several end-products in the
lipid peroxidation pathway, and this method takes no account of the
alternative lipid isomerisation pathway.2 For these reasons some
suggest that a panel of free-radical markers should be adopted,
including those that reflect free-radical damage to non-lipid
constituents of blood and tissues. With this approach we have found
evidence for oxidative stress in patients with cystic fibrosis:
increased quantities of the lipid isomerisation marker 9-ds, 11-trans
linoleic acid (9,11 LA) are present in relation to concentrations of
the natural fatty acid (9,12 LA) in both nasal epithelia and sera and
there is a reduced ratio of bioactive ascorbic acid to total vitamin C in
plasma.4
Increased amounts of pentane are unlikely to be of major
pathogenetic importance. By contrast, other end-products of lipid
oxidation such as hydroxy alkenals (involved in signal transduction
and which are powerful chemotactins) and 9,11 LA (which could be
expected to reduce membrane fluidity) may be more important.
These effects could be relevant to the epithelial transport defects
associated with cystic fibrosis 5 Despite our reservations, breath
hydrocarbon analysis does allow changes in lipid peroxidation as
part of the disease process to be monitored. The dynamic nature of
the investigation and its non-invasiveness are major assets.
Studies have been supported by the Cystic Fibrosis Research Trust.
Adult Cystic Fibrosis Unit,
Monsall Hospital,
Manchester, UK
Department of Gastroenterology and Pharmacy,
Royal Infirmary,







1. Bilton D, Seabra L, Jones M, Webb AK, Braganza JM. High breath pentane levels in
patients with cystic fibrosis. Clin Sci 1990; 79 (suppl): 20P.
2. Guyan PM, Uden S, Braganza JM. Heightened free radical activity in pancreatitis.
Free Radical Biol Med 1990; 8: 347-54.
3. Uden S, Bilton D, Guyan PM, Kay PM, Braganza JM. Rationale for antioxidant
therapy in pancreatitis and cystic fibrosis. In: Emerit I, Packer L, Auclair C, eds.
Antioxidants in therapy and preventive medicine. New York: Plenum Press, 1990:
555-72.
4. Sahl B, Webb AK, Guyan PM, et al. Aberrant free radical activity in cystic fibrosis.
Clin Chim Acta 1989; 181: 65-74.
5. Bilton D, Webb AK, Kay PM, et al. Further evidence for oxidative stress in young
adults with cystic fibrosis. Clin Sci (in press).
Epidermal ICAM-1 in psoriasis after
long-term cyclosporin
SIR,-Dr Barker and colleagues (Jan 26, p 211) suggest that
cyclosporin could act in psoriasis partly through the expression of
epidermal adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1). This is a reasonable assumption because
intralesional cyclosporin reduces expression of ICAM-1 in parallel
with plaque regression.1 Two weeks of oral cyclosporin reduces
ICAM-1 endothelial cell expression if psoriasis has responded.2
When oral cyclosporin was given in alopecia areata, terminal hair
regrowth could be correlated with a fall in ICAM-1 expression by
follicular epithelium.3 However, the effect of long-term oral
cyclosporin on ICAM-1 expression of keratinocytes in chronic
plaque psoriasis has not been reported.
Keratinocyte staining for ICAM-1 with a monoclonal antibody
(RR-1; gift of Prof T. Springer) was measured in 14 patients with
psoriasis. 6 mm punch skin biopsy samples were taken before and
after a three-month course of either 2-5 or 5 mg/kg per day
cyclosporin. Clinical response was very good, with a fall in mean
PASI (psoriasis area severity index) from 13 (SEM 1 8) to 2.7 (07).
ICAM staining usually decreased, but in two patients there was a
considerable increase, despite a satisfactory clinical response as
shown by a fall in PASI score to under 20% of baseline. Both
patients had relapsed to about 60% of their baseline PASI score,
especially around the face, within a month of stopping cyclosporin.
This compares with a relapse of 42% of baseline PASI for the whole
group.
It seems that ICAM-1 expression in psoriasis can still arise
despite a good clinical response, and that it is not essential to the
action of cyclosporin. Variable staining for ICAM-1 in
inflammatory diseases suggests that on its own it is not sufficient for
leucocyte-mediated cytotoxicity to occur and that ICAM-1
expression is unlikely to be the "final common pathway" in the
pathogenesis of such diseases.4 Cyclosporin may be acting through
other mechanisms such as interference with the activation of T
lymphocytes, which is needed for their adhesion to ICAM-bearing
epidermal cells. This corroborates experience in renal allografts
where tubular expression of ICAM-1 can occur despite adequate
treatment with cyclosporin to prevent rejection. We are presently
looking at other integrin molecules to see if better markers for the
action of cyclosporin can be found.
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Growth references
SIR,&mdash;We are often asked about growth references for specific
populations-for example, country, race, or disease specific growth
curves. We describe here minimum criteria for such reference
curves and discuss the complexity and cost of such development.
We focus on weight and height reference curves but some of the
arguments may also be applicable to other anthropometric
measurements. The differences between a "reference" and a
"standard" have been described elsewhere.1 This letter focuses on
the development and use of growth references that provide a point
of comparison but do not necessarily define optimum growth.
Ideally, growth reference curves should be based on a
representative sample of the population. Growth curves should not
be developed from convenient sample data, such as clinic records.
The representativeness (relative to the general population) of such
data are questionable, and the accuracy of the weight, height, and
age information generally cannot be verified. Longitudinal data are
appealing, because of the potential for the determination of growth
velocity, but collecting such data on a representative population is
likely to be prohibitively expensive.
The sample size for developing reference curves must be
adequate to ensure smooth and consistent extreme centile
estimates. Because of distinct growth patterns, separate
curves for males and females should be developed, with at
least 100 males and 100 females at each month of age (at least
for those less than 5 years of age).
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Once the information has been collected and computerised,
complex statistical software is necessary to smooth the data. There is
always the potential to "oversmooth" or "undersmooth", a question
that relates to whether irregularities in the unsmoothed curves are
due to biological processes or to sampling variation. Creating
normalised curves allows the results to be expressed as standard
deviations (Z-scores) and percentiles. To make the reference
curves accessible to researchers and public health workers, new
computer software should be produced to incorporate the new
curves.
Data collection, smoothing, normalisation, and computerisation
of new reference curves is expensive and time-consuming.
Moreover, in countries where local growth curves have been
developed through collecting information on well-nourished
children, the curves generally have differed little from the existing
Centers for Disease Control/World Health Organisation reference
curves.’ The use of local standards can also make it difficult to
compare nutrition status between countries. Any secular changes in
the growth of a population would necessitate updating the local
standard.’
These practical and theoretical considerations obviate creating
race or ethnic specific curves. Although race and ethnic groups may
differ somewhat in average growth, the differences do not generally
become apparent until mid-childhood. Furthermore, they are
usually not substantial’ and do not have a large effect on the
prevalence of anthropometric abnormality (such as more than 2 SD
below the median).
Disease-specific growth curves-for example, for children with
AIDS or cystic fibrosis-present the above complexities plus
others, such as varying disease severity. Advances in the detection
and treatment of disease over time would also necessitate updating
the reference. Disease-specific growth curves may not be
practicable in most settings.
Although the current CDC/WHO international reference is not
without limitations,3 it is adequate and allows researchers to
evaluate the growth pattern of individuals and assess the nutritional
status of populations. We recommend that this reference be used in
the nutritional assessment of individual children and populations.
In developing countries the resources needed to produce a local
growth reference might be more effectively used to meet other
public health needs.
Centers for Disease Control,
Atlanta, Georgia 30333, USA
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Screening for congenital hip dysplasia
SIR,&mdash;Your April 20 editorial draws attention to the confusion
surrounding congenital hip dysplasia.
The failure of clinical screening is not surprising in view of
Leck’sl estimate that there are twenty-two false-positive tests and
one false-negative test for each true positive. Ultrasonography
offers the possibilty of more accurate screening, but expense,
difficulty of use, and variable results with this method have been
given as reasons for persisting with clinical screening.2 Ultrasound
equipment is in regular use in departments of radiology, cardiology,
and obstetrics. If use of the equipment available is rationalised,
ultrasound screening for congenital hip dysplasia would not be
expensive. Radiologists experienced in ultrasonography do not
regard such examination of the infant hip as difficulty A large pilot
study of ultrasound screening of congenital dislocation of the hip
has been done in the UK, with one radiologist scanning 1001 infant
hips.’ It led to a substantial reduction in the number of hips
requiring splinting and demonstrated hip abnormalities in two
babies with normal physical examinations.
Clarke et als who were quoted in the editorial as strong
proponents of a selective approach to ultrasound screening
concluded "We consider that a prospective long-term trial of
ultrasound screening of all births is required". The diagnosis and
managment of congenital dislocation of the hip could be greatly
improved by such a trial.
X-ray Department,
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Percutaneous ethanol injection of
parathyroid adenomas in primary
hyperparathyroidism
SIR,-Dr Monzani and colleagues (March 23, p 743) report
successful treatment of autonomous thyroid nodule with
percutaneous ethanol injection. Ultrasonically guided percutaneous
ethanol injection, which seems to be an efficient technique for
inducing tumour necrosis,’ has also been successful in the treatment
of parathyroid tumours in secondary hyperparathyroidism.2 We
report that ultrasonically guided percutaneous ethanol injection can
also be effective in primary hyperparathyroidism.
6 patients (mean age 79 years) with a confirmed diagnosis of
primary hyperparathyroidism and contraindications for surgery
(severe heart failure in 3, recent myocardial infarction in 2, and
recent stroke in 1) underwent ultrasonically guided percutaneous
ethanol injection of parathyroid adenoma. After the parathyroid
adenoma had been located by echography, 0-5-1 ml ethanol (95%)
was injected with a fine needle, leading to necrosis of the tumour. 5
of the 6 patients were successfully treated by one to three ethanol
injections, with plasma calcium and phosphorus concentrations
becoming normal during follow-up of 6-21 months. In 3 patients,
calcium values were not completely normal after the first ethanol
injection, suggesting an incomplete necrosis of the parathyroid
adenoma and leading to one or two further ethanol injections several
days later, until normal calcium values were achieved. Mean plasma
calcium and parathyroid hormone (PTH) (PTH intact assay;
normal range 20-80 ng/1) were significantly reduced and
phosphorus was significantly higher after ethanol injection (table).
MEAN PLASMA CALCIUM, PHOSPHORUS, AND PTH BEFORE
AND AFTER PERCUTANEOUS ETHANOL INJECTION OF
PARATHYROID ADENOMA IN 5 SUCCESSFULLY TREATED
PATIENTS
PTH = parathyroid hormone.
p < 0-01 (before vs after) for all three variables
